Comparison Of Eplerenone Versus Melatonin As Therapeutic Options For The Treatment Of Chronic Central Serous Chorioretinopathy

LAVAQUE E; GRAMAJO L; REAL J.P; JUAREZ CP; ROSENSTEIN R; LUNA J.D

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

ASSOC RESEARCH VISION OPHTHALMOLOGY INC

Lugar: Rockville, MD 20852; Año: 2017 vol. 58 p. 5932 - 5932

0146-0404

PURPOSE:Compare the efficacy of melatonin and eplerenone for the treatment of chronic central serous chorioretinopathy (CSCR)METHODS:This restrospective trial was conducted on patients with chronic central serous chorioretinopathy, who had previous failed treatments for their condition. A total of 25 patients with chronic CSCR were treated: 20 patients were treated with 50 mg/day of oral eplerenone for 3 months, 10 patients were treated orally with 3 mg melatonin t.i.d for 1 month, and 5 patient were treated with placebo. Primary outcome measure was a change in BCVA at 1and 3 months. Secondary outcome was a change of central macular thickness recorded with OCT at 1 and 3 months of treatment.RESULTS:The central macular thickness showed a significant decrease (P < 0.005) at month of both treatment but change in choroidal thickness was smaller in eplerenone group (P > 0.05 at 1 and 3 months). In terms of BCVA, both groups of treatment showed a mean significant improved from the first month. Although there were no significant differences between groups, melatonin showed a faster effect on BCVA. No changes on BCVA or CMT were noted in the control group.CONCLUSION:Melatonin and eplerenona can be considered equally effective in improving BCVA of patients with CSCR, but melatonin is statistically superior in promoting the reabsorption of SRF and produces apparently faster effects on visual acuity.